This Fifth Amendment to Securities Purchase Agreement (this “Fifth Amendment”) is entered into as of October 9, 2026 (the “Fifth Amendment Effective Date”) by and among Evofem Biosciences, Inc., a Delaware corporation (the “Company”), Ad...
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
